npj Vaccines

npj Vaccines, Published online: 04 May 2026; doi:10.1038/s41541-026-01453-5 Immunogenicity of PCV13 during Hospitalization soon after infection resolution: Vaccis study

npj Vaccines, Published online: 04 May 2026; doi:10.1038/s41541-026-01452-6 The first workshop dedicated to Lassa virus–specific correlates of protection (CoP) was held in 2024 and was convened by the Coalition for Epidemic Preparedness Innovations (CEPI). Experts from multiple disciplines reviewed existing knowledge and identified gaps in understanding Lassa virus- and vaccine-induced immune res…

npj Vaccines, Published online: 02 May 2026; doi:10.1038/s41541-026-01477-x Preexisting IgG forms immune complexes and links local thermal reactogenicity with immunogenicity in influenza vaccination

npj Vaccines, Published online: 02 May 2026; doi:10.1038/s41541-026-01456-2 A TRAC-478-adjuvanted recombinant N1 neuraminidase influenza virus vaccine induces balanced and broadly protective immune responses

npj Vaccines, Published online: 02 May 2026; doi:10.1038/s41541-026-01468-y High affinity is insufficient for strong B cell activation by HIV broadly neutralising antibodies

npj Vaccines, Published online: 02 May 2026; doi:10.1038/s41541-026-01473-1 Lipid nanoparticle-encapsulated DNA vaccine prevented lung consolidation following heterologous influenza A virus challenge in pigs

npj Vaccines, Published online: 02 May 2026; doi:10.1038/s41541-026-01476-y Superior protection against tuberculosis using heterologous mRNA nanoadjuvant vaccines

npj Vaccines, Published online: 27 April 2026; doi:10.1038/s41541-026-01455-3 Protective immunity against malaria by a nanoparticle CIS43-based junctional vaccine alone or in combination with R21

npj Vaccines, Published online: 27 April 2026; doi:10.1038/s41541-026-01462-4 HER-2 therapeutic vaccine is not hampered by concurrent HER-2 monoclonal antibody

npj Vaccines, Published online: 27 April 2026; doi:10.1038/s41541-026-01466-0 Preclinical efficacy of dendritic cells loaded with newly identified HPV11 E6-derived CD8 + T cell epitopes

npj Vaccines, Published online: 27 April 2026; doi:10.1038/s41541-026-01463-3 Influenza mRNA vaccine with engineered panhandle-forming UTRs provides potent, dose-sparing protection against seasonal influenza viruses

npj Vaccines, Published online: 24 April 2026; doi:10.1038/s41541-026-01461-5 Adjuvant-induced macrophage activation compromises BA71ΔCD2-mediated protection against African swine fever virus

npj Vaccines, Published online: 25 April 2026; doi:10.1038/s41541-026-01454-4 An open repository of COVID-19 vaccine mandate studies with a worked scoping review of quasi-experimental evidence

npj Vaccines, Published online: 25 April 2026; doi:10.1038/s41541-026-01464-2 Prefusion-stabilized SARS-CoV-2 spike reshapes antigenic hierarchy and antibody targeting against conserved and occluded epitopes

npj Vaccines, Published online: 22 April 2026; doi:10.1038/s41541-026-01459-z Development of in vitro airway epithelial model to assess immune response and safety of mucosal adjuvants

npj Vaccines, Published online: 22 April 2026; doi:10.1038/s41541-026-01422-y Efficacy of the meningococcal vaccine against Neisseria gonorrhoeae : a randomised clinical trial (MenGO)

npj Vaccines, Published online: 21 April 2026; doi:10.1038/s41541-026-01460-6 Dual-route H5N1 vaccination induces systemic and mucosal immunity in murine and bovine models

npj Vaccines, Published online: 21 April 2026; doi:10.1038/s41541-026-01449-1 Structural and genetic signatures of two classes of HCV E2 neutralizing face antibodies from non-human primates immunized with a recombinant E1E2

npj Vaccines, Published online: 18 April 2026; doi:10.1038/s41541-026-01443-7 BPZE1 vaccination induces IL-17 + and IL-22 + CD4 + T cells associated with nasal mucosal secretory IgA responses in humans: effects on virulent Bordetella pertussis colonisation

npj Vaccines, Published online: 17 April 2026; doi:10.1038/s41541-026-01445-5 Rational selection of antigenic targets for Group A Streptococcus vaccine: updates, challenges and opportunities